aTyr Pharma, based in San Diego, focuses on developing therapies targeting tRNA synthetase biology for fibrosis and inflammation, with efzofitimod as its lead candidate for interstitial lung disease. The company went public on May 7, 2015, and has 56 employees.
Jane A Gross bought 3,750 shares of ATYR on 17 March at $4.00 per share, worth a total of $15K. They now own 9,750 ATYR shares, or a 63% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
